CD19 — Drug Target

All drugs that target CD19 — marketed and clinical-stage. Includes 8 drug classes acting on this target.

Drug classes

Monoclonal antibody · Antibody-Drug Conjugate (ADC) · CAR-T cell therapy · Adoptive cell therapy · CD19-targeting monoclonal antibody · CAR T-cell therapy · Monoclonal antibody-drug conjugate · CAR T cell therapy

Marketed (4)

• REZ · Centers for Disease Control and Prevention · Monoclonal antibody · Oncology
  REZ is a monoclonal antibody that targets the CD19 protein on B cells.
• LONCASTUXIMAB TESIRINE · Antibody-Drug Conjugate (ADC) · Oncology
  Loncastuximab tesirine is an ADC that targets CD19 on B-lineage cells, internalizes, and releases a cytotoxic agent to induce cell death.
• IL-7/IL-15 pre-treated CD19 cells · jiangjingting · CAR-T cell therapy · Oncology
  IL-7/IL-15 pre-treated CD19-targeted CAR-T cells enhance T cell proliferation and persistence to attack CD19-positive B-cell malignancies.
• IL-2 pre-treated CD19 cells · jiangjingting · Adoptive cell therapy · Oncology
  IL-2 pre-treated CD19-targeted cells enhance immune recognition and elimination of CD19-expressing B-cell malignancies through cytokine-primed cellular immunity.

Phase 3 pipeline (7)

• BMS-986393 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · CAR-T cell therapy · Oncology
  BMS-986393 is a CAR-T cell therapy that redirects patient T cells to recognize and kill cancer cells expressing the CD19 antigen.
• Maintenance weekly x4 · Fondazione Italiana Linfomi - ETS · Monoclonal antibody · Oncology
  This drug targets the CD19 protein on B cells to induce apoptosis.
• EG12014 · EirGenix, Inc. · Monoclonal antibody · Oncology
  EG12014 is a monoclonal antibody targeting CD19.
• Liso-cel · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · CAR-T cell therapy · Oncology
  Liso-cel is a CAR-T cell therapy that redirects a patient's own T cells to recognize and kill B cells expressing CD19.
• SEL-212 low-dose · Swedish Orphan Biovitrum · Monoclonal antibody · Oncology
  SEL-212 is a monoclonal antibody targeting CD19.
• monoclonal antibody cA2 · FDA Office of Orphan Products Development · Monoclonal antibody · Oncology
  cA2 targets the CD19 protein on B cells to induce their destruction.
• A arm (DA-90) · Polish Adult Leukemia Group · CD19-targeting monoclonal antibody · Oncology
  DA-90 is a monoclonal antibody targeting CD19.

Phase 2 pipeline (15)

• BTV100 High dose · BioTheraVision, Inc. · CD19-targeting monoclonal antibody · Oncology
  BTV100 is a monoclonal antibody targeting CD19.
• CAR-T-19 cell injection · Beijing Yongtai Ruike Biotechnology Company Ltd · CAR-T cell therapy · Oncology
  CAR-T-19 is a chimeric antigen receptor T-cell therapy engineered to recognize and kill CD19-expressing B-cell malignancies.
• BT086 · Biotest · Monoclonal antibody · Oncology
  BT086 is a monoclonal antibody targeting CD19.
• Cycle 7 Consolidation · Gruppo Italiano Malattie EMatologiche dell'Adulto · CAR-T cell therapy · Oncology
  This drug targets the CD19 protein on B cells to induce cell death.
• CD19 t-haNK- IV Administration · ImmunityBio, Inc. · CAR T-cell therapy · Oncology
  CD19 t-haNK- is a type of immunotherapy that targets and kills cancer cells by harnessing the power of a patient's own immune system.
• Eque-cel CAR-T Therapy · Nanjing IASO Biotechnology Co., Ltd. · CAR-T cell therapy · Oncology
  CAR-T cell therapy targets CD19-positive B cells
• BT061 · Biotest · Monoclonal antibody · Oncology
  BT061 is a monoclonal antibody targeting CD19.
• CSL346 · CSL Behring · Monoclonal antibody · Oncology
  CSL346 is a monoclonal antibody targeting the CD19 protein.
• CAR-T CD19 · Sheba Medical Center · CAR-T cell therapy · Oncology
  Chimeric antigen receptor T-cell therapy targeting CD19
• BTV100 Mid dose · BioTheraVision, Inc. · CD19-targeting monoclonal antibody · Oncology
  BTV100 is a monoclonal antibody targeting CD19.
• ARI-0001 cells · Sara V. Latorre · CAR-T cell therapy · Oncology
  ARI-0001 cells are a type of immunotherapy that stimulate the immune system to attack cancer cells.
• BAX326 · Baxalta now part of Shire · Monoclonal antibody · Oncology
  BAX326 is a monoclonal antibody targeting CD19.
• JCAR017 · Celgene · CAR T-cell therapy · Oncology
  JCAR017 is a CD19-directed CAR T-cell therapy designed to target and eliminate CD19-positive B cells.
• Polatuzumab Vedotin, Rituximab, Lenalidomide · Yan Zhang, MD · Monoclonal antibody-drug conjugate · Oncology
  Monoclonal antibody targeting CD19, conjugated with microtubule inhibitor
• DC-CTL · Shenzhen Hornetcorn Bio-technology Company, LTD · CAR-T cell therapy · Oncology
  DC-CTL is a type of immunotherapy that uses genetically modified T cells to target and kill cancer cells.

Phase 1 pipeline (4)

• Anti-CD19 iCAR NK Cells · Allife Medical Science and Technology Co., Ltd. · CAR T cell therapy · Oncology
  CD19-targeting chimeric antigen receptor (CAR) T cells
• 111In-DAC · Copharos · Monoclonal antibody-drug conjugate · Oncology
  A radiolabeled antibody-drug conjugate targeting CD19
• AIC100 CAR T Cells · AffyImmune Therapeutics, Inc. · CAR T cell therapy · Oncology
  Chimeric antigen receptor T cells targeting CD19
• ATHENA CAR-T · EdiGene Inc. · CAR-T cell therapy · Oncology
  CAR-T cell therapy targeting CD19